Inhibiting Corneal Neovascularization by Targeting Tissue Factor
- Institution
- OHIO STATE UNIVERSITY, OH
- Principal investigator
- Hua Zhu
- Funding
- $433K
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
Project Summary Cornea is a transparent tissue without any vasculature. Diseases and injuries that compromise the optical clarity of the cornea are the third most common cause of blindness worldwide. A common sequela of these corneal diseases and injuries is the growth of pathological vessels, a process known as corneal neovascularization (CNV). To date, there is no specific therapy for CNV, underscoring the need to identify effective treatments for this disease. Tissue factor (TF) is a well-known factor for blood coagulation after blood vessel injury. Under physiological condition, TF is strictly expressed in cells underneath the endothelial cells, such as pericytes. Preliminary study revealed that TF level was low in uninjured mouse corneas and was upregulated after alkali injury. In the proposed work, TF as a potential biomarker for CNV and an immuno-conjugate that targets TF as a potential therapy to treat CNV will be investigated.
Research team
- Zhiwei HuPI
- Hua ZhuPI
LOADING MOONBASE SCORE
Questions for OHIO STATE UNIVERSITY
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Ohio State University46
Maladaptive Remodeling of the Neuromuscular Synapse Following Central Nervous System Injury
Maria Helen Harley Balch · $41K · 2023–2025
- NIH · Ohio State University46
New approach to sustained neuroprotection and enhanced recovery following acute ischemic stroke
Paco S Herson · $565K · 2022–2027
- NIH · Ohio State University46
Defining Novel Mechanisms of Sudden Death in Dravet Syndrome: Dysregulation of Sodium Channels in the Heart
Przemyslaw Radwanski · $382K · 2021–2026